Results 171 to 180 of about 48,636 (310)

The B-cell-autoantibody axis in lung cancer immunity. [PDF]

Theranostics
Huang Y, Hu H, Sun R, Wang Y.
europepmc   +1 more source

Sex differences in genomics, immune microenvironment and immunotherapy response in adult grade 4 gliomas

Clinical and Translational Discovery, Volume 6, Issue 2, April 2026.
Overall survival of patients with brain tumors receiving ICIs treatment Abstract Purpose Sex differences in the prevalence of gliomas have been reported; however, whether there are sex differences in the development and immunotherapy of gliomas remains poorly understood.
Feng Tang, Zhen‐Yuan Liu, Xi Chen, Jin‐Zhou Yang, Zhi‐Qiang Li   +4 more
wiley   +1 more source

Advances in Nanotechnology for Lymphoma Treatment: Targeted Delivery, Immunomodulation, and TME-Responsive Therapy Strategies. [PDF]

Int J Nanomedicine
Han B, Han Z, Zhang Y.
europepmc   +1 more source

Small Intestinal Metastasis From Pulmonary Large Cell Carcinoma Detected by Capsule Endoscopy and Balloon‐assisted Endoscopy, Followed by Early Surgical Resection: A Case Report

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Metastasis of lung cancer to the small intestine is rare and often diagnosed only after life‐threatening complications such as perforation or obstruction. We report a case of small intestinal metastasis from pulmonary large cell carcinoma, diagnosed using balloon‐assisted endoscopy (BAE) performed for obscure gastrointestinal bleeding (OGIB ...
Yoshihiro Yokota, Masashi Ohno, Takayuki Imai, Atsushi Nishida, Takuya Shiratori, Eri Tanaka, Toru Miyake, Masaji Tani, Ryoji Kushima, Takuji Iwashita   +9 more
wiley   +1 more source

Bryostatin enhances CD20 CAR-T therapy efficacy against B-cell lymphoma by overcoming trogocytosis-mediated antigen loss. [PDF]

Front Immunol
Wang X, Sun K, Zhang Z, Zhang L, Cui L, Song S, Wei L.   +6 more
europepmc   +1 more source

An Unusual Case of Classic Hodgkin Lymphoma With Strong Expression of B‐Cell Markers

International Journal of Laboratory Hematology, EarlyView.
Christopher Liwski, Sorin Selegean, Allam Shawwa, David M. Conrad   +3 more
wiley   +1 more source

Twenty Years of Therapeutic Leukocytapheresis in Newly Diagnosed Acute Myeloid Leukemia: Insights From A Single Center

Journal of Clinical Apheresis, Volume 41, Issue 2, April 2026.
ABSTRACT Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy, and 5%–20% of newly diagnosed patients present with hyperleukocytosis (HL). HL, most often defined as WBC > 100 000/μL, is a hematologic emergency associated with severe complications, early mortality, and poor prognosis, requiring immediate intervention.
Vojtech Latal, Ivana Skoumalova, Miroslava Palova, Tomas Szotkowski, Martin Cernan, Jana Navratilova, Helena Urbankova, Zuzana Pikalova, Ludek Raida, Edgar Faber, Tomas Papajik   +10 more
wiley   +1 more source

Integrating B Cell Differentiation Model With Real-World Data Informs Determinants for Antibody-Secreting Cell Depletions in Systemic Sclerosis. [PDF]

CPT Pharmacometrics Syst Pharmacol
Nakada T, Saito R, Ishigaki S, Takei H, Yoshimoto K, Akiyama M, Takeuchi T, Kaneko Y, Miyoshi F.   +8 more
europepmc   +1 more source

Associations Between Body Composition and Intratumoural Immune Cells in Patients With Uterine Cervical Cancer

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 2, April 2026.
ABSTRACT Background In uterine cervical cancer (UCC), reduced muscle mass and radiodensity have been linked to unfavourable clinical outcomes. Our aim was to elucidate the associations between body composition (BC) and intratumoural immune cells in patients with UCC.
Alexey Surov, Anne‐Katrin Höhn, Mattes Hinnerichs, Hans‐Jonas Meyer, Jan Borggrefe   +4 more
wiley   +1 more source

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source